BioCryst: Fourth Quarter Financial Highlights

BioCryst Pharmaceuticals Reports Strong Fourth-Quarter Results

BioCryst Pharmaceuticals Inc., headquartered in Durham, North Carolina, announced a net profit of $245.8 million for the fourth quarter, a significant turnaround from a loss during the same period last year.

The company achieved earnings of $1.12 per share, surpassing the consensus estimate of 7 cents per share from four analysts polled by Zacks Investment Research.

During the quarter, BioCryst generated $406.6 million in revenue.

For the full year, the company recorded a net income of $263.9 million, or $1.21 per share, marking a shift to profitability. Annual revenue reached $874.8 million.

Despite these positive financial results, BioCryst’s stock has declined 3% since the start of the year and is down nearly 9% over the past twelve months.